Ignite Creation Date:
2024-05-05 @ 6:39 PM
Last Modification Date:
2024-10-26 @ 9:36 AM
Study NCT ID:
NCT00526136
Status:
COMPLETED
Last Update Posted:
2008-12-18
First Post:
2007-09-05
Brief Title:
Vernakalant Oral Prevention of Atrial Fibrillation Recurrence Post-Conversion Study
Sponsor:
Advanz Pharma
Organization:
Advanz Pharma
Study Overview
Official Title:
Vernakalant Oral Prevention of Atrial Fibrillation Recurrence Post-Conversion Study
Status:
COMPLETED
Status Verified Date:
2008-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the safety tolerability and efficacy of 3 doses of vernakalant oral 150 mg 300 mg and 500 mg bid administered for up to 90 days in subjects with sustained symptomatic atrial fibrillation AF duration 72 hours and 6 months
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None